Reply to L. Del Mastro and A. Prat

Affiliations

¹ Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.

Comment

Neelima Denduluri et al. J Clin Oncol. 2017.

. 2017 Apr 1;35(10):1139.

doi: 10.1200/JCO.2016.70.9758. Epub 2017 Jan 17.

¹ Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.

No abstract available

Comment on

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME, Wolff AC. Denduluri N, et al. J Clin Oncol. 2016 Jul 10;34(20):2416-27. doi: 10.1200/JCO.2016.67.0182. Epub 2016 Apr 18. J Clin Oncol. 2016. PMID: 27091714
Pertuzumab Use in the Adjuvant Setting: Why Not?
Prat A. Prat A. J Clin Oncol. 2017 Apr 1;35(10):1138. doi: 10.1200/JCO.2016.68.6212. Epub 2017 Jan 17. J Clin Oncol. 2017. PMID: 28095149 No abstract available.
Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer.
Del Mastro L. Del Mastro L. J Clin Oncol. 2017 Apr 1;35(10):1137-1138. doi: 10.1200/JCO.2016.68.2393. Epub 2017 Jan 17. J Clin Oncol. 2017. PMID: 28095150 No abstract available.